DanielChem_CHI said:The liver data is among the strongest non-weight findings in the class.
Pushing back on DanielChem_CHI here. Small molecule does not automatically mean cheap. Price is set by what the market will bear and by patent life, not by cost of goods, and I would not assume the savings reach patients.
One concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.
That is the short version; the long version is somebody else's post.
TirzTom said:Small molecule does not automatically mean cheap.
There is a second half to this that has not been said yet. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsFollowing on from roxy_nash — and this may be the naive question:
Whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is?
OP back with an update, since a thread like this is useless without one.
Update — I was wrong in the opening post, specifically about the direction. Correcting it here rather than editing it away.